Department of Cardiovascular Surgery, Kurashiki Central Hospital, Kurashiki City, Okayama, Japan.
Ann Thorac Surg. 2010 Jun;89(6):1896-900; discussion 1900. doi: 10.1016/j.athoracsur.2010.02.080.
Improvements in the results of percutaneous coronary intervention (PCI) with drug-eluting stents (DES) have been extending their use in patients with all forms of coronary artery disease. The purpose of this study was to compare the midterm clinical results of coronary artery bypass surgery (CABG) and PCI with DES in patients with chronic renal failure on hemodialysis.
From January 2002 to December 2006, 29 patients underwent CABG, and 75 patients underwent PCI with DES. For CABG, 24 patients had off-pump surgery. The mean follow-up was 32.0 +/- 22.0 months for CABG and 23.5 +/- 14.8 months for PCI. Survival, cardiac death, major adverse cardiac events (cardiac death, myocardial infarction, revascularization), and target lesion revascularization were analyzed using the Kaplan-Meier method.
Preoperative characteristics and risk factors were compatible between the groups except for the European System for Cardiac Operative Risk Evaluation (7.3 +/- 2.7 for CABG and 5.0 +/- 2.4 for PCI, p < 0.0001) and the presence of a left main trunk lesion (53.3% for CABG and 18.7% for PCI). Thirty-day mortality was 3.3% for CABG and 4.0% for PCI. The 2-year survival rate was 84.0% for CABG and 67.6% for PCI (p = 0.0271). The cardiac death-free curve at 2 years was 100% for CABG and 84.1% for PCI (p = 0.0122). The major adverse cardiac events-free rate at 2 years was 75.8% for CABG and 31.5% for PCI (p < 0.0001). During the follow-up period, there were 6 late deaths in the CABG group and 27 late deaths (including 6 sudden deaths) in the PCI group.
Coronary artery bypass grafting was superior to PCI with DES in patients with chronic renal failure on hemodialysis in terms of long-term outcomes for cardiac death, major adverse cardiac events, and target lesion revascularization. The DES carried a higher risk for sudden death, which might be associated with stent thrombosis.
药物洗脱支架(DES)经皮冠状动脉介入治疗(PCI)效果的改善已使其在各种形式的冠状动脉疾病患者中得到更广泛的应用。本研究旨在比较慢性肾功能衰竭血液透析患者冠状动脉旁路移植术(CABG)和经皮冠状动脉介入治疗(DES)的中期临床结果。
2002 年 1 月至 2006 年 12 月,29 例行 CABG 术,75 例行 DES 经皮冠状动脉介入治疗。CABG 中 24 例为非体外循环手术。CABG 的平均随访时间为 32.0 ± 22.0 个月,DES 经皮冠状动脉介入治疗的平均随访时间为 23.5 ± 14.8 个月。采用 Kaplan-Meier 法分析生存、心脏死亡、主要不良心脏事件(心脏死亡、心肌梗死、血运重建)和靶病变血运重建。
除欧洲心脏手术风险评估系统(CABG 组为 7.3 ± 2.7,PCI 组为 5.0 ± 2.4,p < 0.0001)和左主干病变的存在(CABG 组为 53.3%,PCI 组为 18.7%)外,两组患者术前特征和危险因素无差异。CABG 组 30 天死亡率为 3.3%,DES 经皮冠状动脉介入治疗组为 4.0%。2 年生存率为 CABG 组 84.0%,DES 经皮冠状动脉介入治疗组为 67.6%(p = 0.0271)。2 年时心脏死亡无事件生存率为 CABG 组 100%,DES 经皮冠状动脉介入治疗组为 84.1%(p = 0.0122)。2 年时主要不良心脏事件无事件生存率为 CABG 组 75.8%,DES 经皮冠状动脉介入治疗组为 31.5%(p < 0.0001)。在随访期间,CABG 组有 6 例晚期死亡,DES 经皮冠状动脉介入治疗组有 27 例晚期死亡(包括 6 例猝死)。
对于慢性肾功能衰竭血液透析患者,冠状动脉旁路移植术在心脏死亡、主要不良心脏事件和靶病变血运重建方面优于经皮冠状动脉介入治疗。DES 导致猝死的风险更高,这可能与支架血栓形成有关。